Michael Martin, Head of Takeda Venture Investments, said: “Investing in early-stage companies like Redpin, who are advancing novel technologies with the potential to provide transformational benefits …
More 4BIO Capital leads Redpin Therapeutics’ $15.5 million Series A Videos